Encompass Health's (EHC) Overweight Rating Reaffirmed at Stephens

Stephens reiterated their overweight rating on shares of Encompass Health (NYSE:EHC - Free Report) in a research report sent to investors on Thursday,Benzinga reports. Stephens currently has a $135.00 price objective on the stock.

Other equities research analysts have also recently issued reports about the stock. Truist Financial reissued a "buy" rating and set a $135.00 price target (up from $116.00) on shares of Encompass Health in a research report on Monday, April 28th. William Blair reissued an "outperform" rating on shares of Encompass Health in a report on Friday, February 7th. KeyCorp increased their target price on shares of Encompass Health from $122.00 to $135.00 and gave the stock an "overweight" rating in a research report on Tuesday, May 27th. UBS Group increased their price target on shares of Encompass Health from $117.00 to $130.00 and gave the stock a "buy" rating in a research report on Monday, April 28th. Finally, Wall Street Zen upgraded shares of Encompass Health from a "buy" rating to a "strong-buy" rating in a research report on Saturday, May 24th. Eight research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $127.00.

Encompass Health Price Performance

EHC traded down $0.05 during midday trading on Thursday, reaching $121.22. 445,076 shares of the company's stock were exchanged, compared to its average volume of 700,537. The firm has a market capitalization of $12.22 billion, a price-to-earnings ratio of 27.18, a price-to-earnings-growth ratio of 2.31 and a beta of 0.89. The company has a quick ratio of 1.04, a current ratio of 1.05 and a debt-to-equity ratio of 0.84. Encompass Health has a one year low of $82.74 and a one year high of $125.46. The business has a 50-day simple moving average of $111.55 and a two-hundred day simple moving average of $102.58.

Encompass Health (NYSE:EHC - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The company reported $1.37 earnings per share for the quarter, topping the consensus estimate of $1.19 by $0.18. The firm had revenue of $1.46 billion during the quarter, compared to analysts' expectations of $1.43 billion. Encompass Health had a net margin of 8.48% and a return on equity of 17.56%. Encompass Health's revenue was up 10.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.12 EPS. As a group, research analysts predict that Encompass Health will post 4.8 EPS for the current year.

Encompass Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Tuesday, July 1st will be given a $0.17 dividend. The ex-dividend date of this dividend is Tuesday, July 1st. This represents a $0.68 annualized dividend and a yield of 0.56%. Encompass Health's payout ratio is presently 14.05%.

Insider Transactions at Encompass Health

In related news, CEO Mark J. Tarr sold 118,384 shares of the business's stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $121.53, for a total transaction of $14,387,207.52. Following the completion of the transaction, the chief executive officer now owns 527,070 shares in the company, valued at $64,054,817.10. The trade was a 18.34% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Elissa Joy Charbonneau sold 4,279 shares of the company's stock in a transaction that occurred on Tuesday, May 6th. The shares were sold at an average price of $116.61, for a total transaction of $498,974.19. Following the transaction, the insider now owns 11,958 shares in the company, valued at $1,394,422.38. The trade was a 26.35% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 132,663 shares of company stock valued at $16,034,082 over the last three months. Corporate insiders own 2.10% of the company's stock.

Hedge Funds Weigh In On Encompass Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in EHC. Charles Schwab Investment Management Inc. increased its position in Encompass Health by 0.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 644,764 shares of the company's stock worth $59,544,000 after purchasing an additional 4,345 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S purchased a new position in shares of Encompass Health in the fourth quarter valued at approximately $4,160,000. US Bancorp DE boosted its stake in shares of Encompass Health by 9.6% in the fourth quarter. US Bancorp DE now owns 1,380 shares of the company's stock valued at $127,000 after purchasing an additional 121 shares during the period. Farallon Capital Management LLC lifted its stake in Encompass Health by 15,266.7% in the fourth quarter. Farallon Capital Management LLC now owns 461,000 shares of the company's stock worth $42,573,000 after acquiring an additional 458,000 shares during the last quarter. Finally, New York State Teachers Retirement System lifted its stake in Encompass Health by 0.3% in the fourth quarter. New York State Teachers Retirement System now owns 76,102 shares of the company's stock worth $7,028,000 after acquiring an additional 200 shares during the last quarter. 97.25% of the stock is owned by hedge funds and other institutional investors.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.